September 22, 2011 (London, United Kingdom) — The European Medicines Agency (EMA) says that it has started a review of orlistat-containing medicines to determine whether the "very rare cases of ...
January 13, 2009 — The addition of the diet drug orlistat (Xenical, Roche Laboratories, Inc; alli, GlaxoSmithKline) to caloric restriction failed to enhance weight loss or improve hepatic outcomes ...
Excess visceral adipose tissue is an important predictor of metabolic risk factors for coronary artery disease. Orlistat is a weight-loss drug (taken in conjunction with a reduced-calorie, low-fat ...
FDA is reviewing new safety information regarding reports of liver-related adverse events in patients taking orlistat. Orlistat is marketed in the United States as a prescription product, Xenical, and ...
FDA Approves Alli(TM) (orlistat 60 Mg Capsules) Over-The-Counter GlaxoSmithKline Consumer Healthcare announces today that the U.S. Food and Drug Administration (FDA) approved the weight-loss product ...
[05-26-2010] The U.S. Food and Drug Administration (FDA) has approved a revised label for Xenical to include new safety information about cases of severe liver injury that have been reported rarely ...
It is well established that combining a reduced calorie, low-fat diet with the lipase inhibitor orlistat results in significantly greater weight loss than placebo plus diet. This weight loss is ...
TOKYO, Jan. 13, 2009-Taisho Pharmaceutical (Taisho) has reached an agreement with Glaxo Group Limited, a subsidiary of GlaxoSmithKline (GSK) plc [Headquarters: U.K.; CEO: Andrew Witty] to grant Taisho ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results